Antibody-drug conjugates (ADCs) are transforming targeted cancer therapy, with innovations in conjugation chemistry and payload-linker technologies driving improvements in efficacy, stability, and ...

NERVIANO, Italy & MILAN--(BUSINESS WIRE)--Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with ...

Data supporting the rationale for Baylink's innovative ADC linker technology enabling delivery of degraders, dual payload antibody drug conjugates, and high drug to antibody ratio chemotherapy will be ...

Chugai Pharmaceutical and Araris Biotech have entered an antibody-drug conjugate (ADC)-focused research collaboration and option-to-license agreement worth up to $780m. Under the deal, Swiss oncology ...

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) ...

Superb internalization profile paired with proprietary linker technology underscore strong efficacy and optimal stability data; first-in-class ADC program currently in IND-enabling studies CAMBRIDGE, ...

NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking 1 cytokine technology in ...

The Festival of Biologics in Basel, Switzerland (October 17, 2024) The 16 th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit in Barcelona, Spain (November 7, 2024) The Antibody ...